Zydus Lifesciences rises 4% on getting approval from USFDA for Mirabegron Tablets
“Zydus was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Mirabegron Extended-Release Tablets, 25 mg and 50 mg and therefore is eligible for 180 days of shared generic drug exclusivity for Mirabegron Extended-Release Tablets, 25 mg and 50 mg,” the company said in a BSE filing.
